RxDoctor Payments Data

David Varon, MD

Gastroenterology · Concord, CANPI 1184702656

Payments from drug & device makers

$1,520in general payments, 2019–2025

Across 46 payments — averaging $33.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aimmune Therapeutics, Inc.$355
  • AbbVie$222
  • Nevro Corp.$220
  • Braintree Laboratories, Inc.$168
  • Medtronic$165
  • Concordia Pharmaceuticals Inc.$154
  • plus $237 from 6 others

What the payments were for

  • Food & beverage$1,37590%
  • Gifts$14510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Aimmune Therapeutics, Inc.3$355
AbbVie(2 entities)12$222
Nevro Corp.3$220
Braintree Laboratories, Inc.4$168
Medtronic1$165
Concordia Pharmaceuticals Inc.16$154
Madrigal Pharmaceuticals1$111
Redhill Biopharma Inc.2$32
Takeda Pharmaceuticals U.S.A., Inc.1$26
Alfasigma USA, Inc.1$24
Johnson & Johnson1$23
Novo Nordisk1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,520 in reported general payments places this provider in the 40th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$132,631
Medicare patients
247
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase31$48,740
CreonLipase/Protease/Amylase13$24,572
SutabSod Sulf/Pot Chloride/Mag Sulf49$7,895
Dexlansoprazole DrDexlansoprazole14$4,681
Colesevelam Hcl13$1,565
Pantoprazole Sodium122$1,410
Sucralfate34$631
Omeprazole51$379
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl15$272
Lansoprazole14$267
EnuloseLactulose12$267
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl15$213
Famotidine37$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$355$48,74031 claims
AbbVieCreon$222$24,57213 claims
Braintree Laboratories, Inc.Sutab$168$7,89549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Concord

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →